header
Local cover image
Local cover image
Image from OpenLibrary

Effect of recombinant activated factor VII (rFVIIa) on intraoperative blood loss during pediatric brain surgery : A clinical and thromboelastographic study / Heba Omar Ahmed Omar ; Supervised Iman Riad M. Abdelaal , Enas M. Ghareeb Elshazly , Mohamed Ibrahem Sonbati

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Heba Omar Ahmed Omar , 2010Description: 158 P. : charts ; 25cmOther title:
  • تأثير العامل السابع معاد الإتحاد النشط على فقدان الدم أثناء العملية في جراحة المخ للأطفال [Added title page title]
Subject(s): Online resources: Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia Summary: There is a clinical need for one or more new hemostatic agents to supplement a help in controlling bleeding in pediatric brain tumor, which cannot be controlled by surgical intervention, local hemostatic agents and transfusion of blood products. Recombinant activated factor VII has been approved by the U.S Food and Drug Administration (FDA) for nearly a decade for the prevention and treatment of bleeding episodes in hemophilic patients with inhibitors to coagulation factor VIII or factor IX
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.01.Ph.D.2010.He.E (Browse shelf(Opens below)) Not for loan 01010110053979000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.01.Ph.D.2010.He.E (Browse shelf(Opens below)) 53979.CD Not for loan 01020110053979000

Thesis (Ph.D.) - Cairo University - Faculty of Medicine - Department of Anaesthesia

There is a clinical need for one or more new hemostatic agents to supplement a help in controlling bleeding in pediatric brain tumor, which cannot be controlled by surgical intervention, local hemostatic agents and transfusion of blood products. Recombinant activated factor VII has been approved by the U.S Food and Drug Administration (FDA) for nearly a decade for the prevention and treatment of bleeding episodes in hemophilic patients with inhibitors to coagulation factor VIII or factor IX

Issued also as CD

There are no comments on this title.

to post a comment.

Click on an image to view it in the image viewer

Local cover image